Genentech Rituxan Promo Effort To Expand With Broader Lymphoma Label
Executive Summary
Genentech will be able to increase promotional activity for its non-Hodgkin's lymphoma treatment Rituxan (rituximab) in the next two months as more indications for the drug come on-label, Chief Operating Officer Myrtle Potter told an analyst meeting in New York City Feb. 21.